Clinical Pharmacology Study Group

Worcester, Massachusetts 01610

0 studies enrolling now · 75 studies all time

What they study most

Active Psoriatic Arthritis, Analgesia, Ankylosing Spondyloarthritis, Arthritis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Chronic Gout, Chronic Pain, Crohn's Disease, Diabetic Neuropathy, Painful, Fibromyalgia, Gout

Studies at this site

• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis — Completed
• Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee — Completed
• Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease — Completed
• Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease — Completed
• A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy — Completed
• Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. — Completed
• A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy — Completed
• Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis — Completed
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease — Completed
• A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip — Completed
• Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) — Completed
• Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) — Completed
• Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate — Completed
• Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect — Completed
• RN624 In Adult Patients With Chronic Low Back Pain — Completed
• A Study of Tanezumab in Adults With Chronic Low Back Pain — Completed
• Tanezumab In Osteoarthritis Of The Hip Or Knee — Stopped early
• Tanezumab In Osteoarthritis Of The Knee (2) — Completed
• Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis — Completed
• Extension Study Of Tanezumab In Osteoarthritis — Stopped early
• Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study — Stopped early
• Long Term Safety Study of Tanezumab in Chronic Low Back Pain — Stopped early
• Tanezumab in Osteoarthritis of the Knee — Completed
• Tanezumab in Osteoarthritis Of The Hip — Completed
• Open-label Extension Study Of RN624 — Completed
• Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy — Completed
• A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab — Stopped early
• Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis — Completed
• A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome — Completed
• Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis — Completed
• Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis — Completed
• PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis — Completed
• A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy — Stopped early
• Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis — Completed
• A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01) — Completed
• A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) — Stopped early
• Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) — Completed
• Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis — Completed
• A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee — Completed
• Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04) — Completed
• Lyme Test Indication Combinations (LyTIC) Study — Stopped early
• Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis — Completed
• Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome — Stopped early
• Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe — Completed
• PF-00489791 For The Treatment Of Raynaud's — Completed
• Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX — Completed
• Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis — Stopped early
• GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy — Completed
• BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis — Completed